Pay in 4 interest-free payments of $7.02 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
Seamless Compatibility: Works with both Luer slip and Luer lock syringes
advanced protocols extend to 6 months with periodic lab monitoring Research status: The primary human evidence for CJC-1295 comes from a 2006 randomized, placebo-controlled phase II trial in healthy adults (Teichman et al., J Clin Endocrinol Metab) showing dose-dependent GH increases of 2- to 10-fold lasting 6+ days and IGF-1 elevations lasting up to 28 days after multiple doses with no serious adverse events
This is the practical reason a reader who is nervous about small-volume accuracy might prefer the 50 mg protocol the trade-off being that each vial carries fewer total doses, as the supply math shows next
$149.99 In stock Research goals: Recovery & Healing Description BPC-157 + TB-500 Blend combines two synthetic peptides commonly studied in tissue-repair and recovery research: BPC-157 (Body Protection Compound-157), a stable gastric pentadecapeptide derived from a human gastric juice fragment, and TB-500 (Ac-LKKTETQ), the N-acetylated 1723 fragment of thymosin beta-4
Whats it like to use CJC-1295 and ipamorelin
Contrasting Preclinical Promise with Human Data The central challenge for clinicians is the stark contrast between the vast, overwhelmingly positive body of preclinical BPC-157 evidence and the near-total absence of published, peer-reviewed human clinical trials
